- Home
- DFLI vs MTVA Comparison
DFLI vs MTVA Comparison
Compare DFLI & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFLI
- MTVA
- Stock Information
- Founded
- DFLI 2020
- MTVA 2014
- Country
- DFLI United States
- MTVA United States
- Employees
- DFLI N/A
- MTVA N/A
- Industry
- DFLI Electronic Components
- MTVA
- Sector
- DFLI Technology
- MTVA
- Exchange
- DFLI Nasdaq
- MTVA NYSE
- Market Cap
- DFLI 15.2M
- MTVA 16.8M
- IPO Year
- DFLI N/A
- MTVA N/A
- Fundamental
- Price
- DFLI $2.09
- MTVA $1.60
- Analyst Decision
- DFLI Strong Buy
- MTVA Strong Buy
- Analyst Count
- DFLI 5
- MTVA 1
- Target Price
- DFLI $15.66
- MTVA $12.00
- AVG Volume (30 Days)
- DFLI 44.0K
- MTVA 23.0K
- Earning Date
- DFLI 04-14-2025
- MTVA 03-27-2025
- Dividend Yield
- DFLI N/A
- MTVA N/A
- EPS Growth
- DFLI N/A
- MTVA N/A
- EPS
- DFLI N/A
- MTVA N/A
- Revenue
- DFLI $48,871,000.00
- MTVA N/A
- Revenue This Year
- DFLI N/A
- MTVA N/A
- Revenue Next Year
- DFLI $50.98
- MTVA N/A
- P/E Ratio
- DFLI N/A
- MTVA N/A
- Revenue Growth
- DFLI N/A
- MTVA N/A
- 52 Week Low
- DFLI $2.50
- MTVA $1.51
- 52 Week High
- DFLI $13.14
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- DFLI 35.46
- MTVA N/A
- Support Level
- DFLI $2.25
- MTVA N/A
- Resistance Level
- DFLI $2.47
- MTVA N/A
- Average True Range (ATR)
- DFLI 0.16
- MTVA 0.00
- MACD
- DFLI 0.01
- MTVA 0.00
- Stochastic Oscillator
- DFLI 26.92
- MTVA 0.00
About DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a highly cost-effective storage solution.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.